Cite
HARVARD Citation
Lepage, C. et al. (2017). Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Digestive and liver disease. 49 (5), pp. 568-571. [Online].